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whichever came ﬁrst. Patients were excluded if they had type-1 diabetes or were pre-
scribed rosiglitazone or troglitazone during the study period, or had stroke, MI, or 
brain injury prior to index date. Cox proportional hazards model was used to estimate 
risk for stroke or MI controlling for demographics, baseline comorbidities, medication 
use and resource utilization. RESULTS: A total of 85,253 patients with T2DM were 
included; total of 9053 (10.62%) patients were on PIO and 76,200 on Non-TZD 
cohort; a total of 178 (1.97%) patients who initiated PIO were hospitalized for stroke 
or MI compared to 1838 (2.41%) patients in the Non-TZD cohort (P  0.001) during 
the follow-up period. The unadjusted incidence ratio for stroke or MI hospitalization 
associated with PIO relative to Non-TZD was 0.789 (95% CI: 0.677–0.921). After 
adjusting for baseline covariates in the multivariate analysis PIO patients were less 
likely to have stroke or MI hospitalization than Non-TZD patients, adjusted hazard 
ratio was 0.854 (95% CI: 0.732–0.997). CONCLUSIONS: T2DM patients initiated 
on pioglitazone were at reduced risk of having stroke or MI hospitalization than 
Non-TZD patients during the follow-up period. The result is consistent with clinical 
trial metaanalyses demonstrating lower risk of stroke or MI with pioglitazone com-
pared to other oral antidiabetic agents.
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Trials powered to show signiﬁcant differences in a combined end-point invariably 
lack power when considering the individual end-points. Analyzing them individually 
leads to wide uncertainty margins which may have important consequences, especially 
when death is included. OBJECTIVES: To develop methods which recognize the 
process underlying the occurrence of endpoints and to analyze whether such methods 
lead to different point estimates and different results in probabilistic sensitivity analy-
ses (PSA). METHODS: Two methods are compared with the “usual” approach, where 
individual events are modeled as the outcomes of a multinomial distribution. The 
ﬁrst method heroically assumes that the risk reduction of the combined endpoints 
can be applied to the total event rate after which a partial multinomial model can 
be used for the events. The second method uses a Bayesian meta-regression which 
is programmed in Winbugs and includes data from earlier trials in the same area 
with and without the inclusion of explanatory variables. The two methods are illus-
trated using MI/stroke free survival as an endpoint from studies concerning lipid 
lowering therapy and studies concerning platelet inhibition. In the ﬁrst, lipid levels 
are included as explanatory variables, in the second an unobserved common process 
is assumed. RESULTS: Analysis of data from six cholesterol trials and ﬁve platelet 
studies shows that assuming that the risk reduction applies to all events reduces 
the uncertainty by between 12–22% without affecting the point estimates. When 
using the Bayesian meta-regression models, the uncertainty is decreased by between 
30%80% with explanatory variables and between 16–45% without explanatory 
variables. However, point estimates may change more substantially as guided by the 
evidence from prior observations. CONCLUSIONS: Using Bayesian meta-regression 
to capture the dependence between endpoints in a combined endpoint-study may 
reduce the uncertainty of PSA results substantially. The magnitude of the reduction 
seems greater than when making heroic assumptions concerning the underlying 
dependence.
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OBJECTIVES: Economic evaluations are increasingly used as tools to inform 
decision-makers about the cost-effectiveness of health technologies. Such evaluations 
are often undertaken during the late stages of the technology development (i.e. 
around the time of product launch or, in some cases, post-launch). However, there 
is an increasing need for the manufacturers of the technology to appraise the 
likely cost-effectiveness of the intervention before making decisions on price and 
indication, as well as to inform the development of clinical trials. METHODS: Due 
to the simpliﬁed nature of such ‘early analyses’, there is no availability of Phase III 
trial data, or evidence of subtle interactions between parameters. The purposes of 
such an analysis are to allow the user to determine the relative importance of 
different parameter inputs, in order to inform decisions on pricing, target populations 
and further research. This presentation outlines the key advantages and limitations 
of early modelling, and how the decision maker should interpret such analyses. 
RESULTS: This study demonstrates that early modelling is a vital exercise even 
(and, sometime, especially) when there is a signiﬁcant lack of cost and effectiveness 
data. Early models can be an effective tool for determining price and target indications. 
A variety of outputs are demonstrated that will maximise the usefulness of such models 
to the decision maker. CONCLUSIONS: Even when there is a lack of Phase III data, 
economic models are a useful tool. However, the approach to modelling in such 
circumstances is signiﬁcantly different to that when ‘full’ models are prepared. This 
study demonstrates how the value of early models can be increased, using a number 
of key outputs.
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Value of information (VOI) is a monetary measure of the impact of uncertainty on a 
decision, quantiﬁed in terms of the expected value of perfect information. When 
uncertainty in control parameters is high, new information will carry high value in 
improving the value of a decision. Conversely, if parameters are known precisely, new 
information would not be considered valuable. VOI analysis is intuitively appealing, 
aims to improve our interpretation of the ﬁndings of health economic evaluations, and 
help plan further work—indeed, it is being declared mandatory in some jurisdictions. 
The implications of inaccurate or incomplete VOI analyses is potentially great, 
however; overestimating VOI leads to wasted funds on unnecessary research and 
delays in getting new treatments to markets, while underestimation exaggerates the 
strength of a possibly false decision. In this research, we provide a conceptual overview 
of VOI and discuss some of the key challenges involved in its proper use, with particu-
lar focus on the elements that are not being discussed: components that may bear the 
largest uncertainty such as the structure of the underlying model, the choice of model-
ing technique and the way in which the core control parameters are formulated and 
estimated.
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Meta-models could reduce simulation time when running probabilistic sensitivity 
analyses (PSA) in complex cost-effectiveness analyses models. OBJECTIVES: To 
compare approximations of PSA outcomes by Ordinary Least Squares (OLS), Spatial 
Interpolation (SI) and Gaussian Process (GP) in terms of accuracy and computation 
time using a simple example. METHODS: Three meta-models are used to ﬁt the 
relationship between inputs and outputs considering a cost-effectiveness model 
addressing cardiovascular treatment and using a selection of well chosen combinations 
of inputs. Using separate models for both incremental costs and incremental effects, 
and varying the number of design-points, accuracy is measured by comparing the Root 
Mean Squared Error (RMSE), as comparing thousand out-of-sample predictions of 
the meta-models with the corresponding outputs of the cost-effectiveness model. 
Computation time was deﬁned as programming and running time. The Gaussian 
Process emulator is used in combination with regression. RESULTS: The PSA results 
of the cost-effectiveness model were not linear (RESET test) in both costs and effects 
but the linear model showed relatively high R-squares (0.7 and 0.85). Based on RMSE, 
the GP gives the best results, followed closely by SI. OLS has the smallest computation 
time, followed by GP and SI. Latter difference mostly explained by difference in pro-
gramming time. The fewer design points for the meta-models, the smaller the gap 
between OLS and the interpolation-based models. CONCLUSIONS: GP/SI had best 
accuracy but needed most computation time, while OLS is quickest but the least 
accurate. The difference in accuracy between SI and GP is explained by the non-
 linearity of the relationship. The superiority of GP over SI decreases with increasing 
numbers of design points.
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OBJECTIVES: The use of in-country reviews in the translation process of PRO mea-
sures is an important process. It allows for an existing language version to be modiﬁed 
for use in another country where the same language is spoken. The following lan-
guages are examples of where this can apply: English, Portuguese, Spanish, Chinese, 
Arabic, Russian and French. If a translation completed for one country is not reviewed 
for use in another, there is a risk that the translation may not be linguistically or cul-
turally valid in the new country. This study sets out to outline the level of changes 
made when carrying out this process. METHODS: A sample of in-country reviews 
was taken from the translation of the POLO Chart measure. A total of 9 languages 
were reviewed. All changes that were made to any of the translations as a result of 
the in-country review were assessed according to whether the change was made as a 
result of a deﬁnitive linguistic and/or cultural difference (in the opinion of the in-
country reviewer) or whether the change was made based on subjective preferences 
on behalf of the reviewer. RESULTS: A total of 213 changes were made across the 
9 languages. The majority (140) of changes made were considered to be essential 
changes which were as a result of linguistic and/or cultural differences between the 
countries. More changes were made to the Chinese, Portuguese, and Spanish transla-
tions than to the English. CONCLUSIONS: In-country reviews are very useful in the 
translation process of PRO measures. A large number of changes made across the 9 
languages and the fact that the majority of changes made to the translations are con-
sidered to be essential based on linguistic and/or cultural differences suggest that the 
in-country review is an important process to undertake.
